Retinalamine lyophilisate for solution for injection 5 mg, 10 vials: profile, composition and research

Reference page for Retinalamine lyophilisate for solution for injection 5 mg, 10 vials. Active substance: Пептидные фракции сетчатки / Retinal peptide fractions.

Key facts

What Retinalamine is

Retinalamine is a preparation based on a complex of low-molecular-weight, water-soluble peptides obtained from retinal tissue. Its active principle is not a single substance but a mixture of related fractions.

It is supplied as a lyophilisate for solution for injection: 5 mg per vial, 10 vials per pack. The powder is dissolved immediately before it is given.

The product is classed as a tissue-specific bioregulator. Its peptides are considered close to the signalling molecules that regulate retinal cell metabolism and repair.

How Retinalamine acts

Tissue specificity

The retinal peptides are selected to match the body's own regulatory molecules. They act mainly on retinal cells rather than on the whole body at once.

Protection of neurons

Studies have noted that the peptides support the synthesis of cytoskeletal proteins, neurotrophic factors and antioxidant defence enzymes. This is linked to a neuroprotective effect.

Microcirculation

Normalisation of the tone and permeability of the vessels of the retina and choroid has also been described, which reduces oedema and improves the nutrition of neurons.

Approved uses

The product is mentioned in degenerative changes of the retina, retinitis pigmentosa, diabetic retinopathy and lesions of the optic nerve. It is often considered as part of combined therapy.

The solution is given intramuscularly, subcutaneously or parabulbarly. The route of administration and the length of the course are set by an ophthalmologist in each case.

The list of conditions and the way the product is used are established by a specialist on the basis of examination. Self-administration of such products is not acceptable.

What the research shows

A large share of the publications are experimental animal studies. They assessed the survival of retinal neurons under photochemical damage and the proliferative activity of pigment epithelial cells.

Clinical studies with large samples and rigorous design are fewer. Some of the work consists of reviews and observations rather than large randomised trials.

Links to the primary sources are given below. Research into peptide retinoprotectors is ongoing, and some conclusions still rest on a limited number of observations.

Published research

Primary sources, verified against PubMed:

• [Retinoprotective effects of Retinalamin studied in an experimental model of photochemical damage to rabbit retinas]., PubMed 34726859 (Vestn Oftalmol, 2021).
• Effects of peptides on proliferative activity of retinal and pigmented epithelial cells., PubMed 12937684 (Bull Exp Biol Med, 2003).
• Inductive activity of retinal peptides., PubMed 12802458 (Bull Exp Biol Med, 2002).
• [Polypeptide bioregulators in the treatment of different-type abiotrophy of the retina]., PubMed 15881150 (Vestn Oftalmol, 2005).

Listed for reference. Publication of a study is not a claim about this particular product.

Precautions

• This is a prescription medicine. Prescribing and running the course belong to an ophthalmologist.
• Injections are given by healthcare professionals, and the solution is prepared immediately before it is given.
• It is contraindicated in hypersensitivity to the components of the product.
• Use during pregnancy or breastfeeding is discussed with a doctor individually.
• Injection-site reactions and allergic responses are possible. Unusual symptoms should be reported to a doctor.
• Tell your doctor about every other medicine you take: interactions are possible.

Frequently asked